Researchmoz added Most up-to-date research on "Global Liver Cirrhosis Market 2016-2020" to its huge collection of research reports.
Cirrhosis of the liver (or liver fibrosis) is a serious condition in which the liver stops functioning properly due to damage and irreversible scarring of the liver tissue. The scarring of the tissue is often caused by long-term exposure to viral infections and toxins such as alcohol. Chronic viral hepatitis and non-alcoholic steatohepatitis can also cause liver cirrhosis. Alcohol-related medications, antiviral medications, and metal chelating agents are used in the treatment of the causes of liver cirrhosis while antibiotics, vitamins, corticosteroids, diuretics, beta-blockers, and laxatives are used for the treatment of the complications of the disease.
Technavios analysts forecast the global liver cirrhosis therapeutics market to grow at a CAGR of 4.36% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global liver cirrhosis therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of liver cirrhosis.
The market is divided into the following segments based on geography:
Americas
APAC
EMEA
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=717654
Technavio's report, Global Liver Cirrhosis Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
F Hoffman La-Roche
GlaxoSmithKline
Gilead Sciences
Johnson & Johnson
Merck
Other prominent vendors
Bristol-Myers Squibb
Conatus Pharmaceuticals
Gwo Xi Stem Cell Applied Technology
Instituto Grifols
Intercept Pharmaceuticals
NGM Biopharmaceuticals
Norgine
Pharmicell
Salix Pharmaceuticals
Stempeutics Research
Market driver
High prevalence of liver cirrhosis
For a full, detailed list, view our report
Market challenge
Adverse effects of drugs
For a full, detailed list, view our report
Market trend
Use of off-label drugs
For a full, detailed list, view our report
Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=717654
Cirrhosis of the liver (or liver fibrosis) is a serious condition in which the liver stops functioning properly due to damage and irreversible scarring of the liver tissue. The scarring of the tissue is often caused by long-term exposure to viral infections and toxins such as alcohol. Chronic viral hepatitis and non-alcoholic steatohepatitis can also cause liver cirrhosis. Alcohol-related medications, antiviral medications, and metal chelating agents are used in the treatment of the causes of liver cirrhosis while antibiotics, vitamins, corticosteroids, diuretics, beta-blockers, and laxatives are used for the treatment of the complications of the disease.
Technavios analysts forecast the global liver cirrhosis therapeutics market to grow at a CAGR of 4.36% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global liver cirrhosis therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of liver cirrhosis.
The market is divided into the following segments based on geography:
Americas
APAC
EMEA
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=717654
Technavio's report, Global Liver Cirrhosis Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
F Hoffman La-Roche
GlaxoSmithKline
Gilead Sciences
Johnson & Johnson
Merck
Other prominent vendors
Bristol-Myers Squibb
Conatus Pharmaceuticals
Gwo Xi Stem Cell Applied Technology
Instituto Grifols
Intercept Pharmaceuticals
NGM Biopharmaceuticals
Norgine
Pharmicell
Salix Pharmaceuticals
Stempeutics Research
Market driver
High prevalence of liver cirrhosis
For a full, detailed list, view our report
Market challenge
Adverse effects of drugs
For a full, detailed list, view our report
Market trend
Use of off-label drugs
For a full, detailed list, view our report
Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=717654
No comments:
Post a Comment